Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

VK reported for 6 months of 2024 by IFRS

8/8/24 VKCO

Sberbank reported for 6 months of 2024 by IFRS

8/8/24 SBER

Ozon launched sales in Azerbaijan

8/8/24 OZON

MTS launches additional share buyback from non-residents

8/8/24 MTSS

Board of Directors of Phosagro recommended that dividends

8/7/24 PHOR

PhosAgro reports for 6 months of 2024 by IFRS

8/7/24 PHOR

Fesco reported for 6 months of 2024 by RAS

8/7/24 FESH

Nauka-Svyaz reported for 6 months of 2024 by RAS

8/7/24 NSVZ

Number of installations of VK Video has grown to 250 thousand per day

8/7/24 VKCO

President of Fesco Arkady Korostelev leaves the company

8/7/24 FESH